Thus, further exploration of the effect of TP53 somatic mutation in each PAM50 subtype across different populations may uncover population-specific data that could clarify the role of TP53 as a predictive or prognostic biomarker for breast cancer. This evidence concerns the gene TP53 and breast cancer.